Olesen JB,Lip GY,Hansen ML,et al.Validation of risk stratification:schemes for predicting stroke and thromboembolism in patients with atrial.fibrillation:nationwide cohort study[J].BMJ,2011,342:d124
[2]
Olesen JB,Torp-Pedersen C,Hansen ML,et a1.The value ofthe CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0.1:a nationwide cohort study[J].Thromb Haemost,2012,107:1172-1179.
[3]
Culebras A,Messé SR,Chaturvedi S,et al.Summary of evidence based guideline update:prevention of stroke in nonvalvular atrial fibrillation:report of the Guideline Development Subcommittee of the American Academy of Neurology[J].Neurology,2014,82(8):716-724.
Camm AJ,Lip GY,De Caterina R,et al.2012 focused update of the ESC guidelines for the management of atrial fibrillation:an update of the 2010 ESC guidelines for the management of atrial fibrillation[J].Eur Heart J,2013,66(1):54.
[8]
Coppens M,Eikelboom JW,Hart RG,et a1.The CHA2DS2-VASc score identifies those patients with atrial fibrillation and a CHADS2score of l who are unlikely to benefit from oral anticoagulant therapy[J].Eur Heart J,2013,34:170-176.
[9]
Gerth A,Nabauer M,Oeff M,et al.Stroke events in patients with CHADS2scores 0 and 1 in a contemporary population of patients with atrial fibrillation:results from the German AFNET registry[J].Eur Heart J,2013,34(suppl):808.
[10]
Friberg L,Rosenqvist M,Lip GY.Net clinical benefit of warfarin in patients with atrial fibrillation:a report from the Swedish atrial fibrillation cohort study[J].Circulation 2012,125(19):2298-2307.